Page last updated: 2024-10-26

valproic acid and Leukemia, Smoldering

valproic acid has been researched along with Leukemia, Smoldering in 3 studies

Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.

Research Excerpts

ExcerptRelevanceReference
"Thirty-one elderly AML/RAEB patients (AML n=25; RAEB n=6) with a high rate of comorbidity were entered in a phase II study with low-dose cytarabine (Ara-C) and VPA."2.76Hematologic improvement and response in elderly AML/RAEB patients treated with valproic acid and low-dose Ara-C. ( Alvaro, MG; Baraldi, A; Ciravegna, G; Corsetti, MT; De Paoli, L; Gatto, S; Levis, A; Perticone, S; Pietrasanta, D; Pini, M; Primon, V; Salvi, F; Tonso, A; Zallio, F, 2011)

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (33.33)29.6817
2010's2 (66.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Möller, I1
Blum, S1
Gattermann, N1
Haas, R1
Habersang, K1
Germing, U1
Kuendgen, A2
Corsetti, MT1
Salvi, F1
Perticone, S1
Baraldi, A1
De Paoli, L1
Gatto, S1
Pietrasanta, D1
Pini, M1
Primon, V1
Zallio, F1
Tonso, A1
Alvaro, MG1
Ciravegna, G1
Levis, A1

Trials

1 trial available for valproic acid and Leukemia, Smoldering

ArticleYear
Hematologic improvement and response in elderly AML/RAEB patients treated with valproic acid and low-dose Ara-C.
    Leukemia research, 2011, Volume: 35, Issue:8

    Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Anticonvulsants; Antimetabolites

2011

Other Studies

2 other studies available for valproic acid and Leukemia, Smoldering

ArticleYear
Repeated responses of an elderly patient with high-risk myelodysplastic syndrome to sequential therapy with tipifarnib, 5-azacitidine, and decitabine.
    Annals of hematology, 2009, Volume: 88, Issue:11

    Topics: Aged; Anemia, Refractory, with Excess of Blasts; Azacitidine; Benzene; Decitabine; DNA (Cytosine-5-)

2009
An inexpensive way to treat elderly patients with high-risk MDS or AML.
    Leukemia research, 2011, Volume: 35, Issue:8

    Topics: Anemia, Refractory, with Excess of Blasts; Anticonvulsants; Antimetabolites, Antineoplastic; Cytarab

2011